Sign Up
Stories
Adial Pharmaceuticals Raises Funds for AD04
Share
Adial Pharmaceuticals Raises Funds for A...
ADMA Biologics CFO Transition Announceme...
ADMA Biologics CFO Transition Revealed
ADOCIA Files 2023 Registration Document
Overview
API
Adial Pharmaceuticals exercises warrants for $3.5 million gross proceeds to support corporate, regulatory, and clinical activities for its drug AD04 targeting Alcohol Use Disorder treatment.
Ask a question
How might the financial injection impact Adial Pharmaceuticals' research and development endeavors for treating Alcohol Use Disorder?
In what ways could advancements in treatments for addiction and related disorders influence public health policies and societal perspectives?
What strategies could Adial Pharmaceuticals employ to enhance the market penetration of its drug AD04?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Mar 2024
Coverage
finan
globe